Our data

All studies were performed by the Cell Biology and Immunology Group, in the Department of Cancer Therapeutics, at Southern Research Institute, Birmingham, Alabama.

Our compounds have been shown to improve survival time in 100% of subjects, and cause complete remission of cancer in over 98% of subjects.

Please read a summary of our studies (below) or our helpful note for the non-scientist. Contact us for more detailed information.

Early studies (Table 1)

In vivo studies were performed whereby the EL-4 lymphoma and the B16F10 melanoma were implanted intraperitoneally in mice. These animals were then treated with our compounds, either Mitogen A, Mitogen B, or a combination of the 2. Treatment was also intraperitoneal.

In our studies using our compound, we demonstrated some success:

  • An 8%-22% increase in long term survival (ILS) for animals with lymphoma, and
  • A 50%-64% increase in long term survival for animals with melanoma, and
  • No deleterious effects were noted in ANY treated animals.

Typically, injecting a treatment into the same cavity where the tumor is implanted gives a standard chemotherapeutic agent the "best chance" for it to work. The treatment and tumor are harbored in the same physical space allowing optimum drug interaction with the tumor cells.

When these 2 tumors were implanted subcutaneously, the results were somewhat better but not dramatic.

The limited success of these early studies, combined with the robust success of our later studies demonstrates that BioMune's most effective treatment works through immune system activation and is not as effective when used as a tumorcidal agent.

Later studies (Table 2)

Studies were then performed whereby the MethA fibrosarcoma and the EL-4 lymphoma were implanted subcutaneously and intraperitonealy and the animals were then treated ORALLY.

The results of these studies showed that:

  • Of 60 animals with subcutaneous cancer, 59 became cancer-free. These results were obtained using either Mitogen A or B alone, or in combination.
  • No untreated animal survived, and no treated animal suffered any deleterious effects.

When the tumors were implanted intraperitoneally, the combination therapy proved most effective:

  • ALL animals with the MethA tumor became cancer-free; and
  • 4 out of 5 animals with the EL-4 lymphoma became cancer-free.
  • Again, no untreated animal survived. In all of our studies, no treated animals suffered any deleterious side effects.

We hypothesize that oral treatment stimulates the arm of the immune system that has long been ignored by the scientific community: the intestinal intraepithelial lymphocytes. These cells are known to express different T-cell receptors and have different activation pathways than those of typical T-cells. There may be a pathway whereby these cells stimulate an immune response against the cancer tumors by interaction with tumor-infiltrating lymphocytes. Both the pathways and mechanisms of these actions need further study as well as optimum dose and treatment regimens.